Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?

Chest

Volumn 130, Issue 6, 2006, Pages 1657-1663

  Chin, Kelly M ^a   Channick, Richard N ^b,c   Rubin, Lewis J ^b  

^a St Paul University Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MC 7381 ^*  (United States)

Author keywords

Illicit drugs; Methamphetamine; Pulmonary hypertension; Risk factors

Indexed keywords

AMPHETAMINE; COCAINE; FENFLURAMINE; METHAMPHETAMINE;

ADULT; AGE DISTRIBUTION; APPETITE DISORDER; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DRUG ABUSE; FEMALE; HUMAN; IDIOPATHIC DISEASE; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 33845942152     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.6.1657     Document Type: Article

References (27)

1. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:5S-12S
2. Collazos J, Martinez E, Fernandez A, et al. Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med 1996; 90:171-174
3. Yakel DL Jr, Eisenberg MJ. Pulmonary hypertension in chronic intravenous cocaine users. Am Heart J 1995; 130:398-399
4. Schaiberger PH, Kennedy TC, Miller FC, et al. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 1993; 104:614-616
5. Olfson M, Gameroff MJ, Marcus SC, et al. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2003; 160:1071-1077
6. Lifetime use of specific stimulants and prescription diet pills. 2003 national household survey on drug abuse, Appendix G. Available at: http://oas.samhsa.gov/NHSDA/2k3NSDUH/appg.htm#tabg.2. Accessed November 17, 2006
7. National survey on drug use and health: the NSDUH report. September 16, 2005. Available at: www.oas.samhsa.gov. Accessed November 17, 2006
8. Chin K, Channick R, Kim N, et al. Most patients with PAH have identifiable risk factors and these risk factors vary by gender [abstract]. Am J Respir Crit Care Med 2004; 171:A56
9. Rich S, Rubin L, Walker A, et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000; 117:870-874
10. Abenhaim L, Monde Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335:609-616
11. Brenot F, Herve P, Petipretz P, et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70:537-541
12. Kneehans S, Sziegoleit W, Krause M, et al. Clinical-pharmacological studies on the effect of mephantermine and methamphetamine on the hemodynamics of the lung circulation [in German]. Z Gesamte Inn Med 1975; 30:227-230
13. Kleerup EC, Wong M, Marques-Magallanes JA, et al. Acute effects of intravenous cocaine on pulmonary artery pressure and cardiac index in habitual crack smokers. Chest 1997; 111:30-35
14. Rothman RB, Ayestas MA, Dersch CM, et al. Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation 1999; 100:869-875
15. Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substances. Pharm Ther 2002; 95:73-78
16. Tseng YT, Padbury JF. Expression of a pulmonary endothelial norepinephrine transporter. J Neural Transm 1998; 105: 1187-1191
17. Marcos E, Fadel E, Sanchez O. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004; 94:1263-1270
18. Belohlavkova S, Simak J, Kokesova A, et al. Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels. J Appl Physiol 2001; 91:755-761
19. Erami C, Zhang H, Ho JG, et al. α(1)Adrenoceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol 2002; 283:H1577-H1587
20. Salvi SS. α1-Adrenergic hypothesis for pulmonary hypertension. Chest 1999; 115:1708-1719
21. Marcos E, Fadel E, Sanchez O, et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004; 94:1263-1270
22. MacLean MR, Deuchar GA, Hicks MN, et al. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 2004; 109:2150-2155
23. The Dasis Report: Primary methamphetamine/amphetamine treatment admissions: 1992-2002. Available at: http://oas. samhsa.gov/2k4/methTX/methTX. htm. Accessed October 10, 2004
24. Wu LT, Pilowsky DJ, Wechsberg WM, et al. Injection drug use among stimulant users in a national sample. Am J Drug Alcohol Abuse 2004; 30:61-83
25. Humbert M, Nunes H, Sitbon O, et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22:459-475
26. Mehta NJ, Khan IA, Mehta RN, et al. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118:1133-1141
27. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167:1433-1439